Drug Profile
SOBI 002
Alternative Names: SOBI-002Latest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator Swedish Orphan Biovitrum
- Class Proteins
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jul 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (IV)
- 16 Jul 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (SC)
- 16 Jul 2015 Discontinued - Phase-I for Inflammation (In volunteers) in United Kingdom (IV)